Biotechnology
– First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways – – ATHENA-SSc-ILD Phase 2 topline results expected first-half 2024 – – FDA has granted Fast Track Designation for PRA023 for the treatment of SSc-ILD – Excerpt from the Press Release: SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) —…
Read More
Dose-escalation and dose-expansion trial evaluating potential of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) initiated and expected to enroll up to approximately 80 patients NGM831 is the second of three programs comprising NGM Bio’s wholly-owned myeloid reprogramming and checkpoint inhibition portfolio to enter the clinic NGM831, NGM707…
Read More
Results Demonstrated Anti-BCMA CAR T Cells Derived from Healthy Donors Had Better Immune Fitness and Killing Activity Phase 1 AlloCAR T™ Trials Underway Evaluating ALLO-715 and ALLO-605 for the Treatment of Relapsed/Refractory Multiple Myeloma BCMA Program Clinical Update Expected by the End of 2022 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 23,…
Read More
Excerpt from the Press Release: SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the initiation of a Phase 1 study of RT-102, an oral formulation of the human parathyroid hormone…
Read More
CiVax™ booster vaccine administered seven months after primary vaccination with COVID-19 adenovirus vaccine shows rapid enhancement of neutralizing antibody responses in non-human primates Neutralizing antibodies against Delta and original strain increased by up to 27-fold within one week and up to 243-fold within three weeks Omicron neutralizing antibody levels were undetectable prior to booster vaccination, and…
Read More
In a Nature Communications Medicine publication, the Verita™ proprietary platform detected 96 percent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Biological Dynamics, Inc. announces the publication of its study, Early-Stage Multi-Cancer Detection Using an Extracellular Vesicle…
Read More
-One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in Patients- -Data Sets Stage for Pivotal Phase 3 HOPE-3 Clinical Trial- Excerpt from the Press Release: SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development…
Read More
ALLO-316 is an allogeneic CAR T therapy candidate targeting CD70, which Has Broad Potential Application Across a Variety of Solid Tumors and Hematologic Malignancies Phase 1 TRAVERSE Trial of ALLO-316 for the Treatment of Renal Cell Carcinoma (RCC) ongoing Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) — Allogene…
Read More
NTLA-5001, a novel T cell receptor (TCR)-T cell therapy, is currently being evaluated in a Phase 1/2a study in adults with persistent or recurrent acute myeloid leukemia Excerpt from the Press Release: CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative…
Read More
– Molecular Intelligence Trials (MI Trials) collaboration will enhance identification of patients with NTRK fusion-positive solid tumors, including primary and metastatic CNS tumors potentially eligible for enrollment in the ongoing PBI-200-101 Phase 1/2 clinical study – Pyramid Biosciences currently developing pipeline of clinical-stage precision medicines, including its lead program PBI-200, a next-generation, highly CNS penetrant…
Read More